Alaíde Maria Rodrigues Pinheiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alaíde Maria Rodrigues Pinheiro has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Ana Kélvia Araújo Arcanjo
Hemocentro Regional de Sobral, Ceará
1 shared publication- Ana Kélvia Araújo Arcanjo
Doutoranda do Programa de Pós-Graduação em Biotecnologia em Saúde Humana e Animal/UECE. ORCID: https://orcid.org/
1 shared publication - Antonia Moemia Lúcia Rodrigues Portela
Docente do Centro Universitário Inta - UNINTA
1 shared publication - Antonio Neudimar Bastos Costa
Centro Universitário Uninta, Brasil
1 shared publication - Carlos Garcia Filho
Secretaria de Saúde do Ceará, Av. Almirante Barroso, 600, Fortaleza, Ceará, 60060-440, Brazil
1 shared publication - Carlos Henrique Nery Costa
Laboratório de Leishmanioses, Centro de Inteligência em Agravos Emergentes e Negligenciados, Brasil, Instituto de Doenças Tropicais “Natan Portella”, Departamento de Medicina Comunitária, Universidade Federal do Piauí, Teresina, PI, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 February 2024
- Published by Uniao Atlantica de Pesquisadores in Concilium
- Vol. 24 (2) , 526-535
Acute l acute lymphoblastic leukemia and CAR-T Cell immunotherapy: a literature review
Introduction: The use of CAR-T cells has shown significant results, representing a transformative new treatment option with potentially lasting and even curative responses. This study aims to comprehend CAR-T cell immunotherapy as an innovation for the treatment of B-lineage acute lymphoblastic leukemia (ALL). Methodology: The research was conducted through a bibliographic search in the Medline, PubMed, and Lilacs databases, using the following descriptors: "Acute lymphoblastic leukemia" OR "CAR-T cells" OR "Immunotherapy" and their respective translations into English, between May 2023 and December 2023. Results: The selected studies demonstrated that ALL is a neoplasia with multifactorial etiology, originating in the bone marrow, leading to uncontrolled proliferation of lymphoblasts. However, chemotherapy, despite being the therapeutic method of choice, is considered nonspecific, as the drugs, besides acting on tumor cells, also compromise normal tissues with a high rate of renewal through mitotic division, such as the bone marrow, resulting in adverse reactions. Conclusion: Based on the obtained results, it was possible to conclude that immunotherapy using CAR-T cells has been showing promising results with satisfactory outcomes.
- 1 February 2024
- Published by Uniao Atlantica de Pesquisadores in Concilium
- Vol. 24 (2) , 526-535
Open AccessAcute l acute lymphoblastic leukemia and CAR-T Cell immunotherapy: a literature review
Introduction: The use of CAR-T cells has shown significant results, representing a transformative new treatment option with potentially lasting and even curative responses. This study aims to comprehend CAR-T cell immunotherapy as an innovation for the treatment of B-lineage acute lymphoblastic leukemia (ALL). Methodology: The research was conducted through a bibliographic search in the Medline, PubMed, and Lilacs databases, using the following descriptors: "Acute lymphoblastic leukemia" OR "CAR-T cells" OR "Immunotherapy" and their respective translations into English, between May 2023 and December 2023. Results: The selected studies demonstrated that ALL is a neoplasia with multifactorial etiology, originating in the bone marrow, leading to uncontrolled proliferation of lymphoblasts. However, chemotherapy, despite being the therapeutic method of choice, is considered nonspecific, as the drugs, besides acting on tumor cells, also compromise normal tissues with a high rate of renewal through mitotic division, such as the bone marrow, resulting in adverse reactions. Conclusion: Based on the obtained results, it was possible to conclude that immunotherapy using CAR-T cells has been showing promising results with satisfactory outcomes.
- Open Access
- 23 January 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S41-S47
Association between clinical outcomes, peripheral blood and cytomorphologic features of bone marrow in visceral leishmaniasis
- 23 January 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S41-S47
Open AccessAssociation between clinical outcomes, peripheral blood and cytomorphologic features of bone marrow in visceral leishmaniasis
- Open Access
- 1 January 2024
- Published by Research, Society and Development in Research, Society and Development
- Vol. 13 (1)
Impact of temporary and involuntary suppression of hydroxyurea treatment on hematological and clinical parameters in patients with sickle cell disease
Objective: Here we investigate the impact of involuntary and temporary interruption of hydroxyurea (HU) treatment in patients with Sickle Cell Disease (SCD). Methods: Clinical and hematological parameters were explored in 30 patients with SCD under treatment with HU. The study was performed in two different periods: 1 - During nine months of involuntary discontinuation (April/2015 to January/2016) and 2 – During nine months after resumption of the treatment (March/2016 to December/2016). Results: The resumption of HU treatment improved the hematological parameters, by increasing levels of hemoglobin (+0.65±0.71), hematocrit (+1.16±2.26), mean corpuscular volume (+8.33±5.89), mean corpuscular hemoglobin (+3.15±2.65). There was a reduction in red blood cell distribution width (-0.66±1.69), reticulocytes (-2.53±1.96), leukocytes (-1122±2764) and platelets numbers (-79.933±162.756). These was followed by a reduction in hospital admissions (-0.30±0.79) and in the number of pain episodes (-0.97±1.19), whereas the denial in episodes of pain crisis increased (+1.43±1.43). After resumption, in period 2, hemoglobin levels were inversely correlated with blood transfusion numbers (p=0.034) and acute thoracic syndrome (p=0.017). The hematocrit was inversely correlated with the number of consultations (p=0.030) and the number of times patients denied crisis (p=0.002). Conclusions: Our study shows that the treatment with HU improves clinical and haematological parameters in patients and highlights the negative effects of the discontinuation of the treatment in the quality of life in patients with SCD.
- 1 January 2024
- Published by Research, Society and Development in Research, Society and Development
- Vol. 13 (1)
Open AccessImpact of temporary and involuntary suppression of hydroxyurea treatment on hematological and clinical parameters in patients with sickle cell disease
Objective: Here we investigate the impact of involuntary and temporary interruption of hydroxyurea (HU) treatment in patients with Sickle Cell Disease (SCD). Methods: Clinical and hematological parameters were explored in 30 patients with SCD under treatment with HU. The study was performed in two different periods: 1 - During nine months of involuntary discontinuation (April/2015 to January/2016) and 2 – During nine months after resumption of the treatment (March/2016 to December/2016). Results: The resumption of HU treatment improved the hematological parameters, by increasing levels of hemoglobin (+0.65±0.71), hematocrit (+1.16±2.26), mean corpuscular volume (+8.33±5.89), mean corpuscular hemoglobin (+3.15±2.65). There was a reduction in red blood cell distribution width (-0.66±1.69), reticulocytes (-2.53±1.96), leukocytes (-1122±2764) and platelets numbers (-79.933±162.756). These was followed by a reduction in hospital admissions (-0.30±0.79) and in the number of pain episodes (-0.97±1.19), whereas the denial in episodes of pain crisis increased (+1.43±1.43). After resumption, in period 2, hemoglobin levels were inversely correlated with blood transfusion numbers (p=0.034) and acute thoracic syndrome (p=0.017). The hematocrit was inversely correlated with the number of consultations (p=0.030) and the number of times patients denied crisis (p=0.002). Conclusions: Our study shows that the treatment with HU improves clinical and haematological parameters in patients and highlights the negative effects of the discontinuation of the treatment in the quality of life in patients with SCD.
- Open Access
- 1 November 2022
- Published by RECIMA21 - Revista Cientifica Multidisciplinar in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 3 (11) , e3112105
CONHECIMENTOS SOBRE HEMOVIGILÂNCIA APLICADA AO PACIENTE AMBULATORIAL: PROTOCOLO DE REVISÃO DE ESCOPO
Objetivo deste trabalho é explorar na literatura, conhecimentos sobre a existência de produtos que visem à assistência ao paciente transfundido em regime ambulatorial, focando na hemovigilância, prevenção e identificação de reações adversas. Utilizando a metodologia de revisão conforme protocolo Scoping review do método JBI. Objetivando ampliar a análise de produções acerca do tema, deste modo, serão selecionados artigos bibliográficos publicados ou não, e todo conhecimento que se possa obter, sob os seguintes critérios de inclusão: narrativas sobre produção de conhecimento e a existência de tecnologias que abranja o olhar sobre a cultura de segurança do paciente que é transfundido, com enfoque no paciente atendido nos ambulatórios e que depois voltarão para os domicílios. Para isso, será realizada um esquema de busca detalhada nas bases de dados: Lilacs, Medline, Embase e Scopus. Serão necessários dois revisores para a busca, triando os títulos e resumos, selecionando conhecimentos do material elegido correspondente. Identificação e análise dos dados selecionados será feita considerando todo material escolhido como pertinente, incluindo-os na revisão e classificando em categorias e temas relevantes.
- 1 November 2022
- Published by RECIMA21 - Revista Cientifica Multidisciplinar in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 3 (11) , e3112105
Open AccessCONHECIMENTOS SOBRE HEMOVIGILÂNCIA APLICADA AO PACIENTE AMBULATORIAL: PROTOCOLO DE REVISÃO DE ESCOPO
Objetivo deste trabalho é explorar na literatura, conhecimentos sobre a existência de produtos que visem à assistência ao paciente transfundido em regime ambulatorial, focando na hemovigilância, prevenção e identificação de reações adversas. Utilizando a metodologia de revisão conforme protocolo Scoping review do método JBI. Objetivando ampliar a análise de produções acerca do tema, deste modo, serão selecionados artigos bibliográficos publicados ou não, e todo conhecimento que se possa obter, sob os seguintes critérios de inclusão: narrativas sobre produção de conhecimento e a existência de tecnologias que abranja o olhar sobre a cultura de segurança do paciente que é transfundido, com enfoque no paciente atendido nos ambulatórios e que depois voltarão para os domicílios. Para isso, será realizada um esquema de busca detalhada nas bases de dados: Lilacs, Medline, Embase e Scopus. Serão necessários dois revisores para a busca, triando os títulos e resumos, selecionando conhecimentos do material elegido correspondente. Identificação e análise dos dados selecionados será feita considerando todo material escolhido como pertinente, incluindo-os na revisão e classificando em categorias e temas relevantes.